慢性乙型肝炎治疗流程修订

背景 全球约有20亿人或全球三分之一人曾感染乙型肝炎病毒(HBV),3.5～4亿人为慢性HBV感染.目前美国HBV感染者为125～200万.     

慢性乙型肝炎病毒感染的疾病进展:病毒持续复制的作用

目前全球大约有3.5亿人感染乙型肝炎病毒(HBV),绝大多数感染者在中国.据估计,大约有1.12亿中国人慢性感染HBV[1],约占全世界感染者的33%.     

慢性乙型肝炎前C区和基本核心启动子突变的临床意义

乙型肝炎病毒（HBV ）全球有高流行率，超过20亿人感染过HBV ，其中约4亿人为慢性 HBV感染，约占世界人口的5％，每年有50万人因肝硬化或肝癌死亡［1-2］，这些表明 HBV具有高度传染性是全球的公共卫生问题。     

乙型肝炎病毒前-前-S基因研究进展

<正>乙型肝炎病毒(HBV)感染呈世界性流行,据世界卫生组织报道[1],全球约20亿人曾感染过HBV,其中3.5亿人为慢性感染者,每年约有100     

乙型肝炎与非酒精性脂肪性肝病的相关性

正乙型肝炎病毒(HBV)感染是目前一个严重的全球性公共卫生问题,据世界性卫生组织(WHO)调查报道,现全球70余亿人中约20亿曾有或仍有HBV感染,其中2.4亿人为慢性HBV感染,而每年因HBV感染所致的肝硬化、肝衰竭和原发性肝细胞癌(HCC)去世的患者达65万人。而我国1~59岁的一般人群中约7.18%(1亿余)人乙型肝炎病毒表面抗原     

慢性乙型肝炎的联合抗病毒治疗

全球约有3.5亿人感染乙型肝炎病毒(HBV).目前抗HBV的主要药物有干扰素(IFN)、拉米夫定(LAM)和阿德福韦(ADV)等,现就有关药物的联合治疗作一简述.     

2014年慢性病毒性肝炎临床诊疗进展

<正>病毒性肝炎(Viral hepatitis)是一个严重的全球公共卫生问题,每年超过100万人死于病毒性肝炎[1]。根据病原学分型,目前已被公认的有甲、乙、丙、丁、戊五种肝炎病毒,其中乙型、丙型和丁型肝炎病毒感染可发展为慢性化,全球超过半数的肝硬化和肝细胞癌(Hepatocellular carcinoma,HCC)由乙型肝炎病毒(Hepatitis B virus,HBV)或丙型肝炎病毒(Hepatitis C     

乙型肝炎病毒感染所致肝细胞异型增生22例临床特征分析

正乙型病毒性肝炎是一种传染性强、传播途径复杂、发病率高、流行面广的常见传染病。我国是乙型病毒性肝炎的高发区,数据显示:全球乙肝病毒携带者约有3.5亿~4亿人,我国约占9 300万人~([1])。我国的肝癌多在乙肝肝硬化的基础上发展而来,我国占全球肝癌病人的55%,其中80%由乙肝病毒引起的。近年来,肝细胞肝癌的发病机制研究有了很大进展,肝细胞异型增生(LCD)被认为是肝细胞肝癌的癌前病变。我们回顾性整理分析了我院2009年1月至2014年10月期间行肝     

乙型肝炎病毒体外培养细胞模型研究进展

正乙型肝炎病毒(HBV)可引起急、慢性感染,与肝硬化及肝癌密切相关。全球约有20亿人曾感染过HBV,其中4亿为慢性HBV感染者,且每年约有50万人死于慢性HBV感染引起的肝硬化、肝细胞癌,另外有4万人死于急性HBV感染[1]。HBV感染一直是全球重要的公共健康问题。目前存在的抗乙肝药物多为干扰素类和核苷(酸)类似物类,可以抑制病毒复     

抗HBV核酶的研究进展

乙型肝炎病毒(HBV)是引起乙型肝炎的病原体，据统计全球HBV慢性携带者的总数超过2．8亿。我国是HBV感染的高发区。据血清流行病学调查HBsAg携带率达10％约1．5亿人。虽然传统的抗病毒药物及新一代的核苷类和干扰素有部分作用，但远期疗效均不显著。寻找新型抗乙型肝炎病毒药物成为迫切需要。     

咽部吞咽的生理解剖学与吞咽障碍的失代偿

0引言吞咽是维持人体生存的重要功能活动.每人每天均必须进行无数次吞咽.对吞咽障碍(deglutitiondisoders,DD)进行有效的预防、诊断和治疗必须了解咽部有关的解剖和功能.1吞咽的生理解剖学“吞咽”不仅指口腔内食团(包括液、固体食物、药物和唾液等)在咽部的通过,而应将之定义为是在构成吞咽通道的唇、舌、腭、咽、喉、食管等各器官肌肉、神经的密切协同下,将吞咽物顺利、安全地运送至胃的全过程[1].食物在口腔内经过咀嚼、搅拌,由唾液润湿,变成食团,然后被吞咽经咽和食管入胃.咀嚼的作用是把大块食物分成小块,并经舌肌、颊肌、颌肌等的搅…     

Preparation and separation of the glucuronide and sulfate conjugates of thyroxine and triiodothyronine

An enzymatic method for synthesis of labelled thyroxine glucuronide (T4G) and triiodothyronine glucuronide (T3G) from labelled thyroxine (T4) and triiodothyronine (T3) is presented. The synthetic glucuronides are completely digested by beta-glucuronidase, with recovery of the parent T4 or T3. They have distinctive elution patterns on HPLC and on Sephadex G25 chromatography, and can be clearly separated from T4 and T3 as well as from synthetic T4 sulfate (T4S) and T3 sulfate (T3S). On LH 20 chromatography, elution of T4G and T3G is intermediate between that of T4 and T3 and that of T4S and T3S. T3G can be well separated from other thyronines by HPLC alone, but T4G coelutes with rT3 on HPLC; these are then separated by adding a Sephadex G25 chromatography step. Biosynthetic 131I-T3G and 125I-T4G from the bile of a cat given 131I-T3 and 125I-T4 had similar HPLC chromatographic patterns to those of synthetic T3G and T4G. That the identified peaks from analysis of the bile were indeed T3G and T4G was confirmed by recovery of the parent T3 and T4 after beta-glucuronidase digestion.     

我国骨关节结核诊治的回顾与展望

骨关节结核是危害人们健康的严重感染性疾病,近95％由他处结核病继发而来.罹患骨关节结核疾病后几乎均将致残,严重影响人们的健康、工作和生活.建国以来在党和国家的关心和支持下,骨关节结核的诊治水平取得了长足进步.时至今日,由于多种原因,学科发展和被重视程度受到一定的制约,同整个医疗行业的发展不相适应.回顾过去,展望未来,我们需要重新审视骨关节结核的诊治方法,努力推进骨关节结核诊疗技术的科学发展.     

妊娠时间与肺结核复发的相关性研究及诊治对策

目的 分析肺结核史患者妊娠时间和肺结核复发间相关性.方法 选取我院收治的有肺结核史的妊娠妇女576例作为研究对象,对其妊娠前肺结核治疗、治愈后妊娠时间、妊娠后复发肺结核等进行分析,总结有肺结核史育龄女性的妊娠时间和肺结核复发之间的关系.结果 肺结核治愈后不同时间段妊娠者的结核复发率比较,差异具有显著性（P＜0.05）,停药后间隔时间越久妊娠,肺结核复发的几率越小.结论 加强孕期痰菌检查,及早发现复发肺结核,提高母婴安全.     

血管通路的评价、选择及并发症防治

随着终末期肾衰竭患者的逐年增多，用于维持性血液透析患者的费用支出也逐年增加，其中相当比例的资金用于血管通路的建立及相关并发症的处理。据Lysaght估计，2001年全球维持性透析患者超过110万人，并以每年7％的速度增长，到2010年将达到200万人，今后10年医疗费用将超过1万亿美元。美国国立卫生研究院(NIH)估计，每年因血管通路建立和相     

Kinetics and persistence of cardiovascular and locomotor effects of immobilization stress and influence of ACTH treatment

Stress triggers crucial responses, including elevated blood pressure and heart rate (HR), to handle the emergency and restore homeostasis. However, continuation of these effects following cessation of the stress is implicated with many stress-related disorders. Here, we examine the kinetics and persistence of cardiovascular and locomotor responses to single and repeated immobilization stress (IMO), with and without prior treatment with adrenocorticotropic hormone (ACTH). Radiotelemetry probes were implanted into male Sprague-Dawley rats to continually monitor mean arterial pressure (MAP), HR and locomotor activity. Rats were subjected to IMO for 2 h daily (10 a.m. to noon, 6 consecutive days). The first IMO induced the greatest change in MAP (about 30 mm Hg) and HR (about 200 bpm). Following each IMO, MAP and HR were elevated during the remaining light phase and in the subsequent dark phase, HR was lower than prior to IMO. We further examined whether elevation of ACTH to a level similar to IMO will elicit similar effects, and if it will alter subsequent responses to IMO. Injection of ACTH (13 IU/kg, s.c.) triggered a short-lived rise in MAP, and decreased HR. After six daily injections of ACTH and recovery time (8 days), rats were immobilized as above. The cardiovascular responses were similar during the IMO, but the ACTH-pretreated group displayed differences following cessation of the IMO. In addition, IMO led to a large reduction of locomotor activity during the dark (normally active) phase to levels similar to the light phase. Following the IMOs, locomotor activity recovered more slowly in the ACTH-pretreated group. The study revealed that IMO-triggered cardiovascular and locomotor responses are evident after termination of the stress. In addition, prior exposure to ACTH delayed recovery in cardiovascular and locomotor functions following cessation of stress.